Prospera Kidney General Nephrology Brochure

Prospera is powered by highly optimized, proprietary cell-free DNA (cfDNA) technology. As part of your tool kit, Prospera assesses all types of kidney transplant rejection with great precision.

Prospera Kidney Transplant Provider Brochure

Prospera assesses all types of kidney transplant rejection with great precision.

Anora Patient Brochure

Find the answers you’re looking for after a miscarriage.

Prospera Patient Brochure

Prospera uses revolutionary tech to enhance the patient and physician’s ability to assess otherwise undetected rejection events that might lead to kidney loss.

Tumor-informed assessment of molecular residual disease

Kasi PM, Dayyani F, Morris V. Poster presentation at: American Society of Clinical Oncologist; May 29-31, 2020; Virtual Meeting. Abstract 4108.

Sequencing of Plasma cfDNA from Patients with Locally Advanced Bladder Cancer ESMP 2018

Studies on different cancer types have shown that circulating tumor DNA (ctDNA) levels can be efficiently used to monitor treatment response and/or detect disease recurrence earlier.

Sequencing of plasma cfDNA from patients with locally advanced bladder cancer AACR 2018

Studies on different cancer types have shown that circulating tumor DNA (ctDNA) levels can be efficiently used to monitor treatment response to neoadjuvant therapy.

Presence of Circulating Tumor DNA in Surgically Resected Renal Cell Carcinoma ESMO 2020

Circulating tumor DNA (ctDNA) has emerged as a promising, non-invasive biomarker for preclinical detection and monitoring of various cancers.

Personalized circulating tumor DNA analysis to monitor colorectal cancer AACR 2018

Early detection of disease recurrence has been shown to improve survival in patients with colorectal cancer (CRC); detection of circulating tumor DNA (ctDNA).

Characterization of Clonal Hematopoiesis of Indeterminate Potential Mutations from Germline

Cancer Care and a Tale of Three Molecular "Genomic" Tests ESHG 2020

Hook N, Wallace J, Zimmermann B, et al. Poster presented at: 2020 European Society of Human Genetics; June 6-9, 2020. Abstract E-P16.04.

Analytical validation of the Signatera RUO Assay AACR 2018

The identification of tumor mutations in circulating cell-free DNA (cfDNA) holds great potential for the noninvasive detection of cancer relapse.

Analysis of Circulating Tumor DNA for Early Relapse Detection in Stage III Colorectal Cancer ESMO 2020

Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for early prediction of relapse across different tumor types.

Serial Circulating Tumor DNA Analysis for Detection of Residual Disease ESMO 2018

Early detection of disease recurrence has been shown to improve survival in patients with colorectal cancer (CRC); detection of circulating tumor DNA (ctDNA).